Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiMO-301, Radiotherapy, and Pembrolizumab in Resectable Head and Neck Cancer
NCT07732634Phase 2Not yet recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 2 trial of RiMO-301 in head and neck cancer (HNC), sponsored by University of Illinois Chicago. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
RiMO-301
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07732634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732634.